Lux Capital

Atrandi Biosciences is a privately held biotechnology company focused on advancing single-cell technology, particularly through next-generation single-cell eukaryotic DNA sequencing. This innovative method enables detailed analysis of genomic alterations and cellular heterogeneity. The company develops proprietary microfluidics technology, which includes hardware systems, consumables, and software services. These tools facilitate user-friendly workflows that empower researchers to explore complex biological systems at the single-cell and single-molecule levels. By enhancing the capabilities of single-cell analysis, Atrandi Biosciences aims to support scientific advancements in the understanding of biology and disease.

Mendaera is a medtech startup that specializes in developing advanced healthcare technologies, with a focus on robotics and diagnostic tools. The company aims to enhance clinical judgment and technical expertise to make high-quality care accessible to all patients across various care facilities. Mendaera's innovative platform, currently in development, combines real-time imaging, robotics, and artificial intelligence to assist physicians in both image acquisition and interpretation. This integration facilitates precise and consistent point-of-care interventions, streamlining the patient journey, accelerating recovery, and reducing overall care costs. By empowering healthcare professionals with these advanced technologies, Mendaera seeks to improve the efficacy and accessibility of medical procedures.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

LabGenius Ltd is a biopharmaceutical company based in London that focuses on discovering new biological molecules through the integration of artificial intelligence, automation, and synthetic DNA. Founded in 2012, the company has developed a robotic platform known as EVA, which acts as a robot scientist capable of designing, conducting, and learning from its own experiments. LabGenius specializes in developing next-generation protein therapeutics aimed at addressing unmet medical needs, including conditions like Inflammatory Bowel Disease. Their innovative approach utilizes advanced machine learning and synthetic biology to engineer the properties of protein drugs, enhancing attributes such as protease stability and tissue penetration. This technology enables the efficient creation of protein therapeutics, providing physicians with access to cutting-edge treatments developed through robotic automation.

Summer Health is a provider of pediatric telehealth services designed to simplify access to healthcare for families. The company enables timely communication with board-certified pediatricians through a text-based platform, allowing users to receive expert answers and reliable advice quickly. Summer Health's services include health tracking and personalized healthcare plans, ensuring that patients can obtain necessary care within minutes. By leveraging digital technology, Summer Health aims to enhance the healthcare experience for families navigating health concerns.

Atavistik Bio is a pre-clinical biotechnology company dedicated to discovering and developing innovative therapies for metabolic diseases and cancer. The company focuses on identifying metabolite-protein interactions and harnessing nature's allosteric control mechanisms to create first-in-class drug candidates. By applying its platform to genetically validated targets, Atavistik Bio aims to advance novel treatments that address significant medical needs in these areas.

Waymark is a company focused on enhancing access to and the quality of healthcare for individuals receiving Medicaid. It offers community-based healthcare services designed to improve health outcomes for Medicaid beneficiaries. The company collaborates with primary care providers and equips community care teams with essential resources, including health plans, insulin education, and training. Through these efforts, Waymark aims to support patients in effectively managing their health and navigating the healthcare system.

Mendaera is a medtech startup that specializes in developing advanced healthcare technologies, with a focus on robotics and diagnostic tools. The company aims to enhance clinical judgment and technical expertise to make high-quality care accessible to all patients across various care facilities. Mendaera's innovative platform, currently in development, combines real-time imaging, robotics, and artificial intelligence to assist physicians in both image acquisition and interpretation. This integration facilitates precise and consistent point-of-care interventions, streamlining the patient journey, accelerating recovery, and reducing overall care costs. By empowering healthcare professionals with these advanced technologies, Mendaera seeks to improve the efficacy and accessibility of medical procedures.

Siren Biotechnology is a biotech company focused on innovating cancer treatment through a unique gene therapy platform. By integrating adeno-associated virus (AAV) gene therapy with cytokine immunotherapy, Siren Biotechnology has developed a novel therapeutic approach. This combination aims to address significant challenges in cancer treatment, including delivery methods, efficacy, and toxicity, ultimately enhancing the elimination of tumor cells and stimulating anti-tumor immunity. Through this redesigned modality, the company seeks to transform the landscape of cancer therapies, offering new hope for patients facing this disease.

Aera Therapeutics is a biotechnology company focused on enhancing the delivery of genetic medicines through its proprietary protein nanoparticle (PNP) platform. This innovative platform utilizes endogenous human proteins to create capsid-like structures that can effectively package and transfer nucleic acid cargo. By addressing the limitations of current delivery technologies, Aera aims to extend the application of genetic medicines across various tissues and disease areas, ultimately benefiting a wider patient population. In addition to its PNP platform, Aera has developed a therapeutic enzyme platform that features novel, compact, and programmable gene-editing enzymes, further advancing its mission to transform the field of genetic medicine.

Aera Therapeutics is a biotechnology company focused on enhancing the delivery of genetic medicines through its proprietary protein nanoparticle (PNP) platform. This innovative platform utilizes endogenous human proteins to create capsid-like structures that can effectively package and transfer nucleic acid cargo. By addressing the limitations of current delivery technologies, Aera aims to extend the application of genetic medicines across various tissues and disease areas, ultimately benefiting a wider patient population. In addition to its PNP platform, Aera has developed a therapeutic enzyme platform that features novel, compact, and programmable gene-editing enzymes, further advancing its mission to transform the field of genetic medicine.

Paradigm is rebuilding the clinical research ecosystem by developing a platform that allows all patients equitable access to trials while improving trial efficiency and lowering barriers to participation for healthcare providers. It is an innovative company that is dedicated to transforming the clinical research ecosystem. Their mission is to create a more accessible and equitable healthcare system by developing a platform that enables patients from diverse backgrounds to participate in clinical trials. Clinical trials are essential for testing and developing new drugs, therapies, and medical devices, but historically, they have been plagued by inefficiencies, barriers to access, and inequities in patient representation. Paradigm aims to solve these challenges by creating a platform that uses technology and data-driven insights to streamline the clinical trial process, making it more efficient, cost-effective, and inclusive. The Paradigm platform is designed to facilitate seamless communication and collaboration among all stakeholders involved in clinical research, including patients, healthcare providers, pharmaceutical companies, and regulatory agencies. By leveraging technology such as AI, machine learning, and predictive analytics, Paradigm can identify and match eligible patients to clinical trials, streamline the recruitment and enrollment process, and provide real-time data insights to all stakeholders. Overall, Paradigm's innovative approach to clinical research has the potential to revolutionize the healthcare industry by improving patient outcomes, reducing healthcare costs, and accelerating the development of new treatments and therapies.

Enveda Biosciences is a biotechnology company focused on drug discovery through the exploration of chemical diversity found in nature. Utilizing AI-powered tools, the company develops a robust database of chemical molecules derived from living organisms. Enveda's platform integrates machine learning, metabolomics, and robotics to analyze natural samples for their chemical structures and biological activities. This innovative approach allows for the efficient identification of potential new medicines, including antibiotics and hypotensives, without the need for isolating individual compounds or conducting extensive experiments. By harnessing nature's hidden chemistry, Enveda aims to accelerate the development of novel therapeutics for the healthcare industry.

Fertilidad Integral specializes in providing fertility care services. A novel idea: Fertility with Kindness: We transform fertility treatment. They approach every story in order to provide customers with professional, thorough, and kind care. They are specialists in wellness, egg freezing, and in vitro pregnancy.

Cajal Neuroscience is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases. By integrating human genetics, functional genomics, and advanced microscopy, the company aims to identify novel therapeutic targets. Cajal utilizes a range of cutting-edge technologies, including high-throughput functional genomics and multi-omics approaches, to screen for targets that significantly influence the progression of neurodegenerative diseases. This comprehensive methodology supports the development of precision medicine, ultimately aiding healthcare professionals in treating patients affected by these conditions.

Maven Clinic operates an on-demand digital care clinic focused on supporting mothers and families through conception, pregnancy, and postpartum phases. The clinic provides access to video appointments and private messaging with a network of women's and family health practitioners, along with a comprehensive family benefits platform. Its services encompass various tracks, including IVF, egg freezing, pregnancy, postpartum, partner support, adoption, surrogacy, and loss, in addition to career coaching and customized training for human resources professionals. Founded in 2014 and headquartered in New York City, Maven Clinic caters to individuals, employers, and healthcare professionals, aiming to enhance family health and well-being through accessible digital care.

WellTheory is a virtual care platform providing autoimmune and inflammatory conditions care services.

Trial Library is an oncology clinical trials company.

Summer Health is a provider of pediatric telehealth services designed to simplify access to healthcare for families. The company enables timely communication with board-certified pediatricians through a text-based platform, allowing users to receive expert answers and reliable advice quickly. Summer Health's services include health tracking and personalized healthcare plans, ensuring that patients can obtain necessary care within minutes. By leveraging digital technology, Summer Health aims to enhance the healthcare experience for families navigating health concerns.

Creyon Bio is a pre-clinical stage company reimagining drug development as it should be, using a data-first approach for generating uniquely powerful datasets and developing machine learning models to uncover the engineering principles that make precision oligonucleotide-based medicines possible for patient populations of all sizes.

Plexium, Inc. is a biotechnology company based in San Diego, California, that specializes in developing targeted protein degradation therapies aimed at treating cancer and neurodegenerative diseases. Founded in 2017, Plexium utilizes a platform that identifies small molecules capable of modulating E3 ligases, which play a crucial role in protein degradation. This platform includes the DELPhe screening technology, designed for high-content readouts from cell-based assays. By harnessing E3 ligases, Plexium's approach enables selective targeting of various cancers, including small cell lung and breast tumors. The company's innovative research extends beyond existing therapies, exploring new drug-like protein degraders and molecular glues to enhance treatment options for cancer and inflammatory diseases.

Kallyope Inc. is a biotechnology company based in New York City that focuses on the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Founded in 2014, Kallyope employs a multidisciplinary approach, integrating technologies such as sequencing, computational biology, neural imaging, and human genetics to deepen the understanding of gut-brain biology. This comprehensive understanding enables the company to create effective and well-tolerated oral medications targeting various health issues, including diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies. With a team of experienced scientists and a strong foundation in drug discovery, Kallyope aims to address significant unmet medical needs through its research and development efforts.

Gandeeva Therapeutics is a precision biotechnology company focused on developing innovative therapeutics by leveraging cryogenic electron microscopy and machine learning to target key protein-protein interactions. The company's structure-guided drug discovery platform includes target prediction and validation, hit identification through virtual and fragment library screening, and lead optimization. Gandeeva has established a strong preclinical oncology pipeline aimed at addressing challenging cancers with unique protein interaction modulators, including interfacial glues and allosteric inhibitors. Headquartered in the Greater Vancouver area, Canada, Gandeeva is dedicated to enhancing the drug discovery process and reducing the risk of late-stage clinical failures.

Gameto is a biotechnology company focused on improving female reproductive health through innovative therapies. Recognizing that women's health is an underserved area with limited treatment options, Gameto aims to develop advanced solutions that enhance patient outcomes. The company utilizes cellular engineering to create female reproductive cell lines, employing proprietary combinations of transcription factors to reprogram human induced pluripotent stem cells (hiPSCs) into engineered ovarian and endometrial cell lines that function similarly to natural cells. This platform supports a portfolio of cellular therapeutics targeting various female reproductive diseases. Gameto's flagship program, Fertilo, is designed to enhance the processes of in vitro fertilization (IVF) and egg freezing, making them shorter, safer, and more effective. Additional applications of Gameto's technology include Deovo, an organoid of the female reproductive system, and Ameno, a cell-based therapeutic aimed at alleviating the health issues associated with primary ovarian insufficiency and menopause.

Waymark is a company focused on enhancing access to and the quality of healthcare for individuals receiving Medicaid. It offers community-based healthcare services designed to improve health outcomes for Medicaid beneficiaries. The company collaborates with primary care providers and equips community care teams with essential resources, including health plans, insulin education, and training. Through these efforts, Waymark aims to support patients in effectively managing their health and navigating the healthcare system.

Nomic is a bioengineering company focused on making the human proteome as accessible as the human genome. The company is developing the nELISA, a next-generation platform for measuring proteins at high throughput and scale. Nomic provides scientists with protein profiling solutions, allowing them to determine the scope and scale of their experiments. Their platform features cost-effective measurement of protein data and integrates smoothly with industry-standard cytometers for high-throughput analysis. Additionally, Nomic's technology enables the development of custom protein panels, leveraging nanotechnology to use DNA as a versatile linker to address issues of cross-reactivity in protein measurement.

H1 is a healthcare data analytics company based in New York, founded in 2017. It offers a global platform that connects life sciences companies, hospitals, academic medical centers, and health systems with healthcare providers, clinical research opportunities, and industry experts. The platform focuses on delivering real-time data to support decision-making throughout the therapeutic development process, from fundraising to product launch. By providing access to comprehensive information on healthcare professionals and institutions, H1 facilitates connections within the healthcare ecosystem, enabling organizations and professionals to gain live insights that accelerate the discovery and development of therapies aimed at combating diseases.

Pager, Inc. operates an on-demand service platform that connects patients with healthcare services in various settings, including their homes, offices, and hotels. The company offers a mobile application that addresses urgent care needs such as infections, fevers, and allergies, while also providing services like nurse chat, teleconsultations, screening, vaccinations, and prescription delivery. Pager aims to improve healthcare access and decision-making by employing a flexible platform that serves health plans and systems, enhancing consumer experience through information, guidance, and coordination. By integrating clinical and service teams with advanced technology, Pager facilitates triage, telemedicine, appointment scheduling, and health advocacy, fostering a comprehensive care experience. The company, incorporated in 2013 and based in New York, supports over 15 million covered lives in the United States and Latin America.

Atavistik Bio is a pre-clinical biotechnology company dedicated to discovering and developing innovative therapies for metabolic diseases and cancer. The company focuses on identifying metabolite-protein interactions and harnessing nature's allosteric control mechanisms to create first-in-class drug candidates. By applying its platform to genetically validated targets, Atavistik Bio aims to advance novel treatments that address significant medical needs in these areas.

AllStripes is a healthcare technology company focused on accelerating the development of treatments for rare diseases. The company has created a platform that produces regulatory-ready evidence to support rare disease research and drug development. This platform operates as a two-sided network where patients with rare diseases and advocacy groups contribute valuable information, while life science companies utilize this data to identify new drug candidates. Additionally, AllStripes offers a patient application that allows individuals to engage in treatment research online and leverage their own medical data, fostering a collaborative environment aimed at advancing medical research for rare conditions.

Maven Clinic operates an on-demand digital care clinic focused on supporting mothers and families through conception, pregnancy, and postpartum phases. The clinic provides access to video appointments and private messaging with a network of women's and family health practitioners, along with a comprehensive family benefits platform. Its services encompass various tracks, including IVF, egg freezing, pregnancy, postpartum, partner support, adoption, surrogacy, and loss, in addition to career coaching and customized training for human resources professionals. Founded in 2014 and headquartered in New York City, Maven Clinic caters to individuals, employers, and healthcare professionals, aiming to enhance family health and well-being through accessible digital care.

Carbon Health is a technology-driven healthcare company founded in 2015 and headquartered in San Francisco, California. It provides a comprehensive primary care experience through a mobile application that allows users to manage their treatment plans, prescriptions, and lab reports in one place. The company emphasizes convenience and accessibility, offering omnichannel care through various platforms, including clinics, pop-up sites, and virtual consultations. Additionally, Carbon Health has developed a coronavirus assessment tool and has implemented COVID-19 testing services in California, further expanding its commitment to accessible healthcare.

Enveda Biosciences is a biotechnology company focused on drug discovery through the exploration of chemical diversity found in nature. Utilizing AI-powered tools, the company develops a robust database of chemical molecules derived from living organisms. Enveda's platform integrates machine learning, metabolomics, and robotics to analyze natural samples for their chemical structures and biological activities. This innovative approach allows for the efficient identification of potential new medicines, including antibiotics and hypotensives, without the need for isolating individual compounds or conducting extensive experiments. By harnessing nature's hidden chemistry, Enveda aims to accelerate the development of novel therapeutics for the healthcare industry.

Dyno Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative adeno-associated virus (AAV) vectors for gene therapy applications. Founded in 2018, the company employs an artificial intelligence-powered platform that integrates next-generation DNA synthesis, high-throughput sequencing, and machine learning. This advanced approach allows Dyno Therapeutics to design and optimize cell-targeting capsids, which are crucial for the effective and safe delivery of gene therapies. By leveraging its technology, the company aims to provide medical researchers with novel AAV vectors that enhance the efficacy of in vivo therapeutic solutions.

Multiply Labs specializes in the production of personalized pharmaceutical capsules that cater to the unique needs of individual patients. The company leverages a combination of pharmaceutical science and advanced robotics technology to create these tailor-made capsules. Its innovative approach includes operating a state-of-the-art robotic manufacturing facility, which allows for the efficient production of individualized drugs at a reduced cost. Multiply Labs stands out as a pioneer in the industry, being the first to introduce 3D printed capsules, thereby transforming how medications are customized to meet the specific metabolic requirements of patients.

SteadyMD, Inc. is a healthcare company that offers online primary care services throughout the United States. Established in 2016 and headquartered in St. Louis, Missouri, with an additional office in Westlake Village, California, SteadyMD connects patients with board-certified clinicians through its digital platform. This service enables patients to address various medical conditions, dietary preferences, and lifestyles via telehealth consultations, including text, call, or video chat options. The company not only serves direct-to-consumer needs but also provides a B2B telehealth infrastructure, allowing partners to enhance their telehealth offerings efficiently across all 50 states. By focusing on personalized care and utilizing advanced technology, SteadyMD aims to improve access to quality healthcare for patients with complex issues and chronic illnesses.

DeepSpin GmbH, founded in 2019 and based in Berlin, Germany, specializes in developing artificial intelligence-powered magnetic resonance imaging (MRI) equipment. The company’s innovative technology aims to provide MRI imaging systems that are significantly smaller, lighter, and more cost-effective than traditional models. By leveraging generative topological design and deep learning techniques, DeepSpin's MRI machines enhance accessibility to medical imaging, making it available to a wider range of patients globally. This approach seeks to improve healthcare standards in various medical fields previously lacking adequate imaging solutions.

Plexium, Inc. is a biotechnology company based in San Diego, California, that specializes in developing targeted protein degradation therapies aimed at treating cancer and neurodegenerative diseases. Founded in 2017, Plexium utilizes a platform that identifies small molecules capable of modulating E3 ligases, which play a crucial role in protein degradation. This platform includes the DELPhe screening technology, designed for high-content readouts from cell-based assays. By harnessing E3 ligases, Plexium's approach enables selective targeting of various cancers, including small cell lung and breast tumors. The company's innovative research extends beyond existing therapies, exploring new drug-like protein degraders and molecular glues to enhance treatment options for cancer and inflammatory diseases.

H1 is a healthcare data analytics company based in New York, founded in 2017. It offers a global platform that connects life sciences companies, hospitals, academic medical centers, and health systems with healthcare providers, clinical research opportunities, and industry experts. The platform focuses on delivering real-time data to support decision-making throughout the therapeutic development process, from fundraising to product launch. By providing access to comprehensive information on healthcare professionals and institutions, H1 facilitates connections within the healthcare ecosystem, enabling organizations and professionals to gain live insights that accelerate the discovery and development of therapies aimed at combating diseases.

Workit Health, Inc. is a provider of online therapeutic content and professional counseling services focused on substance use recovery. Established in 2014 and based in Ann Arbor, Michigan, the company operates the Workit platform, which offers clinically proven telemedicine treatment for substance use disorder, including online therapy, medication-assisted treatment, psychiatric support, and primary care. Workit Health's services are designed to help individuals achieve long-term recovery from drugs and alcohol while minimizing disruption to their daily lives. The platform facilitates access to on-demand, in-person, and virtual medical and psychosocial support, catering to a wide range of clients including employers, educational institutions, healthcare facilities, and recovery communities. Additionally, Workit Health provides accredited opioid addiction treatment featuring buprenorphine, enhancing its commitment to harm reduction in addiction care. The company has locations in California, New Jersey, Alaska, and Washington.

LabGenius Ltd is a biopharmaceutical company based in London that focuses on discovering new biological molecules through the integration of artificial intelligence, automation, and synthetic DNA. Founded in 2012, the company has developed a robotic platform known as EVA, which acts as a robot scientist capable of designing, conducting, and learning from its own experiments. LabGenius specializes in developing next-generation protein therapeutics aimed at addressing unmet medical needs, including conditions like Inflammatory Bowel Disease. Their innovative approach utilizes advanced machine learning and synthetic biology to engineer the properties of protein drugs, enhancing attributes such as protease stability and tissue penetration. This technology enables the efficient creation of protein therapeutics, providing physicians with access to cutting-edge treatments developed through robotic automation.

Thrive Earlier Detection Corp. is a healthcare company that specializes in developing advanced blood testing technologies for early cancer detection. Its flagship product, CancerSEEK, is a liquid biopsy test that analyzes genomic mutations in tumor DNA and protein markers in plasma, allowing for the identification of various cancers at their nascent stages, often before symptoms manifest. Founded in 2018 and headquartered in Cambridge, Massachusetts, with an additional office in Baltimore, Maryland, Thrive aims to integrate cancer screening into standard medical practice. The company leverages real-world data and machine learning to enhance the accuracy of cancer detection, facilitate follow-up testing, and streamline the transition to oncological care. Thrive operates as a subsidiary of Exact Sciences Corporation and has received investments from notable firms including Third Rock Ventures and Section 32.

Braid Health, Inc., founded in 2018 and headquartered in San Francisco, California, specializes in developing artificial intelligence-driven diagnostic tools for radiology. The company offers an AI-powered diagnostic collaboration platform that enhances the speed, quality, and workflow of radiologists and healthcare providers. By integrating AI diagnostics with the expertise of board-certified radiologists, Braid Health supports real-time quality assurance and facilitates seamless integration with Electronic Health Records (EHR). This innovative approach allows healthcare professionals to deliver accurate diagnoses efficiently, improving overall patient care and access to medical imaging services.

AllStripes is a healthcare technology company focused on accelerating the development of treatments for rare diseases. The company has created a platform that produces regulatory-ready evidence to support rare disease research and drug development. This platform operates as a two-sided network where patients with rare diseases and advocacy groups contribute valuable information, while life science companies utilize this data to identify new drug candidates. Additionally, AllStripes offers a patient application that allows individuals to engage in treatment research online and leverage their own medical data, fostering a collaborative environment aimed at advancing medical research for rare conditions.

Pager, Inc. operates an on-demand service platform that connects patients with healthcare services in various settings, including their homes, offices, and hotels. The company offers a mobile application that addresses urgent care needs such as infections, fevers, and allergies, while also providing services like nurse chat, teleconsultations, screening, vaccinations, and prescription delivery. Pager aims to improve healthcare access and decision-making by employing a flexible platform that serves health plans and systems, enhancing consumer experience through information, guidance, and coordination. By integrating clinical and service teams with advanced technology, Pager facilitates triage, telemedicine, appointment scheduling, and health advocacy, fostering a comprehensive care experience. The company, incorporated in 2013 and based in New York, supports over 15 million covered lives in the United States and Latin America.

Kallyope Inc. is a biotechnology company based in New York City that focuses on the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Founded in 2014, Kallyope employs a multidisciplinary approach, integrating technologies such as sequencing, computational biology, neural imaging, and human genetics to deepen the understanding of gut-brain biology. This comprehensive understanding enables the company to create effective and well-tolerated oral medications targeting various health issues, including diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies. With a team of experienced scientists and a strong foundation in drug discovery, Kallyope aims to address significant unmet medical needs through its research and development efforts.

Adimab LLC is a biotechnology company based in Lebanon, New Hampshire, focused on the discovery, development, and optimization of human monoclonal and bispecific antibodies. Founded in 2007, Adimab utilizes an integrated antibody discovery platform that accelerates the process from antigen identification to the production of purified, full-length human IgGs. The company specializes in various antibody formats, including IgG, scFv, and CD3-based bispecific antibodies, which are designed to meet stringent criteria for affinity, epitope coverage, and cross-reactivity. Adimab's innovative approach enables its partners to enhance their biologics pipelines and effectively address therapeutic needs in areas such as cancer, autoimmune, and infectious diseases through a range of technology access arrangements.

Cajal Neuroscience is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases. By integrating human genetics, functional genomics, and advanced microscopy, the company aims to identify novel therapeutic targets. Cajal utilizes a range of cutting-edge technologies, including high-throughput functional genomics and multi-omics approaches, to screen for targets that significantly influence the progression of neurodegenerative diseases. This comprehensive methodology supports the development of precision medicine, ultimately aiding healthcare professionals in treating patients affected by these conditions.

LabGenius Ltd is a biopharmaceutical company based in London that focuses on discovering new biological molecules through the integration of artificial intelligence, automation, and synthetic DNA. Founded in 2012, the company has developed a robotic platform known as EVA, which acts as a robot scientist capable of designing, conducting, and learning from its own experiments. LabGenius specializes in developing next-generation protein therapeutics aimed at addressing unmet medical needs, including conditions like Inflammatory Bowel Disease. Their innovative approach utilizes advanced machine learning and synthetic biology to engineer the properties of protein drugs, enhancing attributes such as protease stability and tissue penetration. This technology enables the efficient creation of protein therapeutics, providing physicians with access to cutting-edge treatments developed through robotic automation.

Variant Bio Inc. is a biotechnology company based in Seattle, Washington, that focuses on developing therapeutics through the study of human genetic diversity. Founded in 2018, the company identifies individuals and populations that exhibit extreme traits of medical significance, utilizing advanced sequencing technologies and analytic methods to uncover the genes and pathways associated with these traits. By leveraging insights from genetic research, Variant Bio aims to discover new therapeutic targets for conditions such as neurodegenerative, autoimmune, and cardiometabolic diseases. The company's innovative approach combines statistical genetics and machine learning, enhancing the potential for genomic drug discovery to address unmet medical needs.

Kallyope Inc. is a biotechnology company based in New York City that focuses on the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Founded in 2014, Kallyope employs a multidisciplinary approach, integrating technologies such as sequencing, computational biology, neural imaging, and human genetics to deepen the understanding of gut-brain biology. This comprehensive understanding enables the company to create effective and well-tolerated oral medications targeting various health issues, including diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies. With a team of experienced scientists and a strong foundation in drug discovery, Kallyope aims to address significant unmet medical needs through its research and development efforts.

Visla Labs Inc. is a San Francisco-based startup focused on developing an artificial intelligence platform tailored for the radiology and healthcare sectors. Incorporated in 2018, the company is dedicated to advancing healthcare technology, aiming to create innovative solutions that enhance diagnostic processes and patient care. With venture capital backing, Visla Labs is positioned for significant growth as it approaches a critical milestone in its development.

Braid Health, Inc., founded in 2018 and headquartered in San Francisco, California, specializes in developing artificial intelligence-driven diagnostic tools for radiology. The company offers an AI-powered diagnostic collaboration platform that enhances the speed, quality, and workflow of radiologists and healthcare providers. By integrating AI diagnostics with the expertise of board-certified radiologists, Braid Health supports real-time quality assurance and facilitates seamless integration with Electronic Health Records (EHR). This innovative approach allows healthcare professionals to deliver accurate diagnoses efficiently, improving overall patient care and access to medical imaging services.

AllStripes is a healthcare technology company focused on accelerating the development of treatments for rare diseases. The company has created a platform that produces regulatory-ready evidence to support rare disease research and drug development. This platform operates as a two-sided network where patients with rare diseases and advocacy groups contribute valuable information, while life science companies utilize this data to identify new drug candidates. Additionally, AllStripes offers a patient application that allows individuals to engage in treatment research online and leverage their own medical data, fostering a collaborative environment aimed at advancing medical research for rare conditions.

Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Senti Biosciences is a clinical-stage biotechnology company specializing in synthetic biology and gene circuit engineering for therapeutic purposes. The company employs its Gene Circuits platform to develop innovative therapies that enhance precision in targeting cancer cells while avoiding damage to healthy cells. Senti Bio's approach involves the use of allogeneic chimeric antigen receptor natural killer (CAR-NK) cells that incorporate its gene circuit technologies, aimed at addressing various oncology indications. Among its product candidates are SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to selectively eliminate cancer cells without harming healthy bone marrow, and SENTI-301A, which targets hepatocellular carcinoma. Senti Biosciences aims to provide effective treatment options for difficult-to-treat diseases through advanced cell and gene therapies.

Kallyope Inc. is a biotechnology company based in New York City that focuses on the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Founded in 2014, Kallyope employs a multidisciplinary approach, integrating technologies such as sequencing, computational biology, neural imaging, and human genetics to deepen the understanding of gut-brain biology. This comprehensive understanding enables the company to create effective and well-tolerated oral medications targeting various health issues, including diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies. With a team of experienced scientists and a strong foundation in drug discovery, Kallyope aims to address significant unmet medical needs through its research and development efforts.

Pager, Inc. operates an on-demand service platform that connects patients with healthcare services in various settings, including their homes, offices, and hotels. The company offers a mobile application that addresses urgent care needs such as infections, fevers, and allergies, while also providing services like nurse chat, teleconsultations, screening, vaccinations, and prescription delivery. Pager aims to improve healthcare access and decision-making by employing a flexible platform that serves health plans and systems, enhancing consumer experience through information, guidance, and coordination. By integrating clinical and service teams with advanced technology, Pager facilitates triage, telemedicine, appointment scheduling, and health advocacy, fostering a comprehensive care experience. The company, incorporated in 2013 and based in New York, supports over 15 million covered lives in the United States and Latin America.

Physera, Inc. is a company focused on delivering digital musculoskeletal care by connecting patients with physical therapists through a mobile application. Founded in 2015 and based in Palo Alto, California, the platform provides patients suffering from musculoskeletal injuries with access to tailored workout plans, along with features such as in-app animations and voice prompts designed to facilitate exercise therapy and alleviate pain. The application collects data to help assess the effectiveness of these routines, enabling physical therapists to create targeted recovery and maintenance plans that can be coordinated remotely. Physera serves a diverse clientele, including patients with muscular pain, self-insured employers, and large health plans. As of May 2020, Physera operates as a subsidiary of Omada Health, Inc.

Workit Health, Inc. is a provider of online therapeutic content and professional counseling services focused on substance use recovery. Established in 2014 and based in Ann Arbor, Michigan, the company operates the Workit platform, which offers clinically proven telemedicine treatment for substance use disorder, including online therapy, medication-assisted treatment, psychiatric support, and primary care. Workit Health's services are designed to help individuals achieve long-term recovery from drugs and alcohol while minimizing disruption to their daily lives. The platform facilitates access to on-demand, in-person, and virtual medical and psychosocial support, catering to a wide range of clients including employers, educational institutions, healthcare facilities, and recovery communities. Additionally, Workit Health provides accredited opioid addiction treatment featuring buprenorphine, enhancing its commitment to harm reduction in addiction care. The company has locations in California, New Jersey, Alaska, and Washington.

3Scan is turning tissue into bits by building robotic microscopy tools and software for large-scale sample analysis and 3D visualizations. Many diseases emerge only at a tissue level, such as cancer, heart disease, lung disease, stroke, Alzheimer's, and diabetes. 3Scan enables higher throughput, greater quantification, and broader image analysis than what is currently possible with traditional histopathology. 3Scan's data-driven approach is expanding our understanding of tissue biology and will lead to the discovery of new diagnostics and therapeutics. The company was founded in 2011 and is headquartered in San Francisco, California.

Kala Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Watertown, Massachusetts, that specializes in developing therapies for diseases affecting mucosal tissues using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology. This innovative approach enhances drug distribution and pharmacokinetics by delivering biocompatible, drug-loaded particles that uniformly coat mucosal surfaces. The company's lead product candidate, KPI-121 0.25%, has successfully completed two Phase III clinical trials aimed at providing temporary relief for dry eye disease. Additionally, INVELTYS, another product, has also completed two Phase III trials for treating inflammation and pain following ocular surgery. Kala is advancing its pipeline, including KPI-285, a receptor tyrosine kinase inhibitor for retinal diseases, which is currently in preclinical studies. The company aims to address significant clinical needs while exploring research collaborations to enhance its product offerings.

Kallyope Inc. is a biotechnology company based in New York City that focuses on the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Founded in 2014, Kallyope employs a multidisciplinary approach, integrating technologies such as sequencing, computational biology, neural imaging, and human genetics to deepen the understanding of gut-brain biology. This comprehensive understanding enables the company to create effective and well-tolerated oral medications targeting various health issues, including diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies. With a team of experienced scientists and a strong foundation in drug discovery, Kallyope aims to address significant unmet medical needs through its research and development efforts.

Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Pager, Inc. operates an on-demand service platform that connects patients with healthcare services in various settings, including their homes, offices, and hotels. The company offers a mobile application that addresses urgent care needs such as infections, fevers, and allergies, while also providing services like nurse chat, teleconsultations, screening, vaccinations, and prescription delivery. Pager aims to improve healthcare access and decision-making by employing a flexible platform that serves health plans and systems, enhancing consumer experience through information, guidance, and coordination. By integrating clinical and service teams with advanced technology, Pager facilitates triage, telemedicine, appointment scheduling, and health advocacy, fostering a comprehensive care experience. The company, incorporated in 2013 and based in New York, supports over 15 million covered lives in the United States and Latin America.

Pager, Inc. operates an on-demand service platform that connects patients with healthcare services in various settings, including their homes, offices, and hotels. The company offers a mobile application that addresses urgent care needs such as infections, fevers, and allergies, while also providing services like nurse chat, teleconsultations, screening, vaccinations, and prescription delivery. Pager aims to improve healthcare access and decision-making by employing a flexible platform that serves health plans and systems, enhancing consumer experience through information, guidance, and coordination. By integrating clinical and service teams with advanced technology, Pager facilitates triage, telemedicine, appointment scheduling, and health advocacy, fostering a comprehensive care experience. The company, incorporated in 2013 and based in New York, supports over 15 million covered lives in the United States and Latin America.

3Scan is turning tissue into bits by building robotic microscopy tools and software for large-scale sample analysis and 3D visualizations. Many diseases emerge only at a tissue level, such as cancer, heart disease, lung disease, stroke, Alzheimer's, and diabetes. 3Scan enables higher throughput, greater quantification, and broader image analysis than what is currently possible with traditional histopathology. 3Scan's data-driven approach is expanding our understanding of tissue biology and will lead to the discovery of new diagnostics and therapeutics. The company was founded in 2011 and is headquartered in San Francisco, California.

Capella BioScience specializes in the discovery and development of monoclonal antibodies (mAbs) aimed at creating therapeutics for oncology, autoimmune diseases, and other medical conditions. The company employs proprietary technologies to innovate in the development and commercialization of mAbs-based medicines. In addition to its independent efforts, Capella collaborates with biotechnology firms and academic institutions to advance its research and expand the reach of its therapeutic solutions.

Pager, Inc. operates an on-demand service platform that connects patients with healthcare services in various settings, including their homes, offices, and hotels. The company offers a mobile application that addresses urgent care needs such as infections, fevers, and allergies, while also providing services like nurse chat, teleconsultations, screening, vaccinations, and prescription delivery. Pager aims to improve healthcare access and decision-making by employing a flexible platform that serves health plans and systems, enhancing consumer experience through information, guidance, and coordination. By integrating clinical and service teams with advanced technology, Pager facilitates triage, telemedicine, appointment scheduling, and health advocacy, fostering a comprehensive care experience. The company, incorporated in 2013 and based in New York, supports over 15 million covered lives in the United States and Latin America.

Kala Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Watertown, Massachusetts, that specializes in developing therapies for diseases affecting mucosal tissues using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology. This innovative approach enhances drug distribution and pharmacokinetics by delivering biocompatible, drug-loaded particles that uniformly coat mucosal surfaces. The company's lead product candidate, KPI-121 0.25%, has successfully completed two Phase III clinical trials aimed at providing temporary relief for dry eye disease. Additionally, INVELTYS, another product, has also completed two Phase III trials for treating inflammation and pain following ocular surgery. Kala is advancing its pipeline, including KPI-285, a receptor tyrosine kinase inhibitor for retinal diseases, which is currently in preclinical studies. The company aims to address significant clinical needs while exploring research collaborations to enhance its product offerings.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Cerulean Pharma Inc. is a privately-held biopharmaceutical company specializing in the development of innovative nanotechnology-based therapeutics aimed at treating oncology, cardiovascular, autoimmune, and inflammatory diseases. The company focuses on nanoparticle-drug conjugates that target tumors, reduce toxicity, and facilitate therapeutic combinations. Among its notable products is Ovaprene, a contraceptive designed to offer hormone-free protection for multiple weeks. Cerulean has established a distinguished management team and advisory board, drawing from extensive experience in product development and scientific innovation from renowned institutions and companies in the biopharmaceutical sector.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Genocea Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patients' CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. Genocea is advancing several immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, and GEN-011, a neoantigen adoptive T cell therapy. Additionally, the company has developed GEN-003, an immunotherapy aimed at treating genital herpes, and is working on personalized cancer vaccines through its pre-clinical immuno-oncology program. Established in 2006, Genocea aims to address significant unmet medical needs with its targeted therapeutic approaches.

Kala Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Watertown, Massachusetts, that specializes in developing therapies for diseases affecting mucosal tissues using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology. This innovative approach enhances drug distribution and pharmacokinetics by delivering biocompatible, drug-loaded particles that uniformly coat mucosal surfaces. The company's lead product candidate, KPI-121 0.25%, has successfully completed two Phase III clinical trials aimed at providing temporary relief for dry eye disease. Additionally, INVELTYS, another product, has also completed two Phase III trials for treating inflammation and pain following ocular surgery. Kala is advancing its pipeline, including KPI-285, a receptor tyrosine kinase inhibitor for retinal diseases, which is currently in preclinical studies. The company aims to address significant clinical needs while exploring research collaborations to enhance its product offerings.

Cerulean Pharma Inc. is a privately-held biopharmaceutical company specializing in the development of innovative nanotechnology-based therapeutics aimed at treating oncology, cardiovascular, autoimmune, and inflammatory diseases. The company focuses on nanoparticle-drug conjugates that target tumors, reduce toxicity, and facilitate therapeutic combinations. Among its notable products is Ovaprene, a contraceptive designed to offer hormone-free protection for multiple weeks. Cerulean has established a distinguished management team and advisory board, drawing from extensive experience in product development and scientific innovation from renowned institutions and companies in the biopharmaceutical sector.

Genocea Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patients' CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. Genocea is advancing several immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, and GEN-011, a neoantigen adoptive T cell therapy. Additionally, the company has developed GEN-003, an immunotherapy aimed at treating genital herpes, and is working on personalized cancer vaccines through its pre-clinical immuno-oncology program. Established in 2006, Genocea aims to address significant unmet medical needs with its targeted therapeutic approaches.

Cerulean Pharma Inc. is a privately-held biopharmaceutical company specializing in the development of innovative nanotechnology-based therapeutics aimed at treating oncology, cardiovascular, autoimmune, and inflammatory diseases. The company focuses on nanoparticle-drug conjugates that target tumors, reduce toxicity, and facilitate therapeutic combinations. Among its notable products is Ovaprene, a contraceptive designed to offer hormone-free protection for multiple weeks. Cerulean has established a distinguished management team and advisory board, drawing from extensive experience in product development and scientific innovation from renowned institutions and companies in the biopharmaceutical sector.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Genocea Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patients' CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. Genocea is advancing several immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, and GEN-011, a neoantigen adoptive T cell therapy. Additionally, the company has developed GEN-003, an immunotherapy aimed at treating genital herpes, and is working on personalized cancer vaccines through its pre-clinical immuno-oncology program. Established in 2006, Genocea aims to address significant unmet medical needs with its targeted therapeutic approaches.

Cerulean Pharma Inc. is a privately-held biopharmaceutical company specializing in the development of innovative nanotechnology-based therapeutics aimed at treating oncology, cardiovascular, autoimmune, and inflammatory diseases. The company focuses on nanoparticle-drug conjugates that target tumors, reduce toxicity, and facilitate therapeutic combinations. Among its notable products is Ovaprene, a contraceptive designed to offer hormone-free protection for multiple weeks. Cerulean has established a distinguished management team and advisory board, drawing from extensive experience in product development and scientific innovation from renowned institutions and companies in the biopharmaceutical sector.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Genocea Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patients' CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. Genocea is advancing several immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, and GEN-011, a neoantigen adoptive T cell therapy. Additionally, the company has developed GEN-003, an immunotherapy aimed at treating genital herpes, and is working on personalized cancer vaccines through its pre-clinical immuno-oncology program. Established in 2006, Genocea aims to address significant unmet medical needs with its targeted therapeutic approaches.

Cerulean Pharma Inc. is a privately-held biopharmaceutical company specializing in the development of innovative nanotechnology-based therapeutics aimed at treating oncology, cardiovascular, autoimmune, and inflammatory diseases. The company focuses on nanoparticle-drug conjugates that target tumors, reduce toxicity, and facilitate therapeutic combinations. Among its notable products is Ovaprene, a contraceptive designed to offer hormone-free protection for multiple weeks. Cerulean has established a distinguished management team and advisory board, drawing from extensive experience in product development and scientific innovation from renowned institutions and companies in the biopharmaceutical sector.

Cerulean Pharma Inc. is a privately-held biopharmaceutical company specializing in the development of innovative nanotechnology-based therapeutics aimed at treating oncology, cardiovascular, autoimmune, and inflammatory diseases. The company focuses on nanoparticle-drug conjugates that target tumors, reduce toxicity, and facilitate therapeutic combinations. Among its notable products is Ovaprene, a contraceptive designed to offer hormone-free protection for multiple weeks. Cerulean has established a distinguished management team and advisory board, drawing from extensive experience in product development and scientific innovation from renowned institutions and companies in the biopharmaceutical sector.

mPharma is a company focused on improving access to affordable medications for patients in emerging markets. Established in 2013 by Gregory Rockson, Daniel Shoukimas, and James Finucane, mPharma collaborates with pharmaceutical manufacturers, health insurance providers, financial institutions, and governments to facilitate the direct delivery of prescription drugs to consumers. The company offers a pharmaceutical data analytics platform that assists pharmacies in managing their inventory effectively, ensuring that essential chronic disease medications are available at sustainable prices. By enabling doctors, patients, and pharmacists to connect with a network of high-quality medicines, mPharma aims to enhance the overall accessibility and affordability of healthcare for underserved populations.